{"id":"dp303c","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL6068184","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DP303c works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.","oneSentence":"DP303c is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:55.326Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07241936","phase":"PHASE1, PHASE2","title":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-11-13","conditions":"Advanced Solid Tumors","enrollment":444},{"nctId":"NCT06577376","phase":"PHASE1, PHASE2","title":"A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-08-26","conditions":"Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past","enrollment":252},{"nctId":"NCT06313086","phase":"PHASE3","title":"DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-03-13","conditions":"HER2-positive Breast Cancer","enrollment":442},{"nctId":"NCT05901935","phase":"PHASE3","title":"DP303c in Patients With HER2-positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-07","conditions":"HER2-positive Advanced Breast Cancer","enrollment":420},{"nctId":"NCT05810103","phase":"PHASE1","title":"A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-04-06","conditions":"HER2-positive Advanced Solid Tumors","enrollment":12},{"nctId":"NCT05334810","phase":"PHASE2","title":"DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2022-05-01","conditions":"HER2-positive Breast Cancer","enrollment":191},{"nctId":"NCT04828616","phase":"PHASE2","title":"Study of DP303c Injection in Patients With Advanced Ovarian Cancer","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-07","conditions":"Ovarian Cancer","enrollment":104},{"nctId":"NCT04826107","phase":"PHASE2","title":"Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-08","conditions":"Gastric Cancer","enrollment":196},{"nctId":"NCT04146610","phase":"PHASE1","title":"Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2019-11","conditions":"Neoplasms","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DP303c treatment","DP303c"],"phase":"phase_3","status":"active","brandName":"DP303c","genericName":"DP303c","companyName":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","companyId":"cspc-zhongqi-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DP303c is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}